Molecular Mechanisms of HIV Protease Inhibitors Against HPV-Associated Cervical Cancer: Restoration of TP53 Tumour Suppressor Activities [PDF]
Frontiers in Molecular Biosciences, 2022 Cervical cancer is a Human Papilloma virus-related disease, which is on the rise in a number of countries, globally. Two essential oncogenes, E6 and E7, drive cell transformation and cancer development.
Lilian Makgoo +2 more
doaj +2 more sources
Susceptibility of HPV-18 Cancer Cells to HIV Protease Inhibitors [PDF]
VirusesCervical cancer cases continue to rise despite all the advanced screening and preventative measures put in place, which include human papillomavirus (HPV) vaccination.
Lilian Makgoo +2 more
doaj +2 more sources
Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design [PDF]
Molecules, 2021 SARS-CoV-2 is highly homologous to SARS-CoV. To date, the main protease (Mpro) of SARS-CoV-2 is regarded as an important drug target for the treatment of Coronavirus Disease 2019 (COVID-19). Some experiments confirmed that several HIV protease inhibitors
Wei Yu +14 more
doaj +2 more sources
Drug Reprofiling to Identify Potential HIV-1 Protease Inhibitors
Molecules, 2023 The use of protease inhibitors in human immunodeficiency virus type 1 (HIV-1) treatment is limited by adverse effects, including metabolic complications. To address these challenges, efforts are underway in the pursuit of more potent and less toxic HIV-1
Pavimol Angsantikul +2 more
exaly +3 more sources
HIV protease inhibitors restore amphotericin B activity against Candida. [PDF]
PLoS ONECandida auris is an invasive fungal pathogen, representing a global public health threat. It is characterized by high mortality rates among infected individuals, significant antifungal resistance, and a remarkable ability to persist in healthcare ...
Yehia Elgammal +2 more
doaj +2 more sources
HIV protease inhibitors: a review of molecular selectivity and toxicity [PDF]
HIV/AIDS: Research and Palliative Care, 2015 Zhengtong Lv,* Yuan Chu,* Yong Wang Department of Immunology, School of Basic Medical Science, Xiangya School of Medicine, Central South University, Changsha, Hunan, People's Republic of China *Both authors contributed equally to this work ...
Lv Z, Chu Y, Wang Y
doaj +2 more sources
Current and Novel Inhibitors of HIV Protease
Viruses, 2009 The design, development and clinical success of HIV protease inhibitors represent one of the most remarkable achievements of molecular medicine. This review describes all nine currently available FDA-approved protease inhibitors, discusses their ...
Pavlina Rezacova +2 more
exaly +3 more sources
Molecular dynamics simulation of docking structures of SARS-CoV-2 main protease and HIV protease inhibitors [PDF]
Journal of Molecular Structure, 2021 W B Cardoso, Mendanha Sebastiao A
exaly +2 more sources
HIV Protease: Historical Perspective and Current Research
Viruses, 2021 The retroviral protease of human immunodeficiency virus (HIV) is an excellent target for antiviral inhibitors for treating HIV/AIDS. Despite the efficacy of therapy, current efforts to control the disease are undermined by the growing threat posed by ...
Irene T. Weber +2 more
doaj +1 more source
Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometry. [PDF]
PLoS ONE, 2010 HIV protease inhibitors must penetrate into cells to exert their action. Differences in the intracellular pharmacokinetics of these drugs may explain why some patients fail on therapy or suffer from drug toxicity.
Jeroen J A van Kampen +10 more
doaj +1 more source